Keywords: b-ms, backs, off, higher, offer, imclone, following

B-MS backs off higher offer for ImClone

Article | 13 October 2008

Print This

Following Eli Lilly's $70-a-share counter bid for US biotechnology firm ImClone, Bristol-Myers Squibb, which had been trying to gain control ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in